[ad_1] Brokerage firm Citi on Wednesday, March 5, upgraded its rating on Lupin Ltd. and revised its price target higher by 19%. The brokerage upgraded the stock to “buy” from its earlier rating of “sell” and increased its price target to ₹2,260 from its previous target of ₹1,900. This indicates a 15.7% upside potential for […]
Lupin shares in focus after Q3 profit increases nearly 40% – CNBC TV18
[ad_1] Lupin shares are in focus after the company reported its third quarter earnings on Wednesday, February 12. Company Value Change %Change The company reported a profit after tax of ₹8,589 crore, a 38.8% increase from the previous year’s ₹6,187 crore. Its total revenue from operations was up 102.7% at ₹57,677 crore from last fiscal’s […]
Lupin beats Q2 estimates with 74% profit surge, margin expansion – CNBC TV18
[ad_1] Lupin Limited delivered a strong financial performance for the second quarter, surpassing market expectations. Net profit for Q2 stood at ₹852.6 crore, comfortably beating the CNBC-TV18 poll estimate of ₹746.7 crore. Revenue came in at ₹5,672.7 crore, outpacing the forecasted ₹5,564.8 crore, while EBITDA reached ₹1,340.4 crore against an expected ₹1,220.4 crore. The company’s […]
Lupin says USFDA issues three observations for its Pithampur facility – CNBC TV18
[ad_1] Pharma major Lupin on Saturday, September 28, said the United States Food and Drug Administration (USFDA) has issued three observations each on the API and finished product side of its Pithampur facility. The USFDA inspected the facility from September 16 to September 27. The pharma company said it is addressing the observations comprehensively and […]